A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
for Macular Degeneration
51 locations incl. Scottsdale
Sponsor: EyeBiotech Ltd.
Sex: All·Age: 50+
Code: NCT07440225·Phase 2, Phase 3·Recruiting·Listed Feb 2026
Cincinnati Eye Institute
Clinical research site in Cincinnati, Ohio · 6552 COPPERLEAF LN, CINCINNATI, OH 45230-2444 · (513) 400-4781 · Website
Part of Cincinnati Eye Institute
As of July 2026, 14 paid clinical trials are recruiting at Cincinnati Eye Institute in Cincinnati, Ohio. Active studies at this site cover conditions such as Cone Rod Dystrophy, Juvenile Macular Degeneration and Stargardt Disease. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Cincinnati Eye Institute (14)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
for Age-related Macular Degeneration (AMD)
140 locations incl. Chandler
Sponsor: Regeneron Pharmaceuticals
Sex: All·Age: 50 - 85
Code: NCT06541704·Phase 3·Recruiting·Listed Aug 2024
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
for Geographic Atrophy
45 locations incl. Tucson
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 60+
Code: NCT06635148·Phase 2·Recruiting·Listed Oct 2024
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
for Primary Open Angle Glaucoma
24 locations incl. Glendale
Sponsor: AbbVie
Sex: All·Age: 45+
Code: NCT06822738·Phase 3·Recruiting·Listed Feb 2025
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
for Neovascular Age-Related Macular Degeneration (nAMD)
54 locations incl. Scottsdale
Sponsor: 4D Molecular Therapeutics
Sex: All·Age: 50+
Code: NCT07064759·Phase 3·Recruiting·Listed Jul 2025
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
for AMD
65 locations incl. Phoenix
Sponsor: AbbVie
Sex: All·Age: 50 - 89
Code: NCT05407636·Phase 3·Recruiting·Listed Jun 2022
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
for Macular Telangiectasia Type 2 (MacTel)
23 locations incl. La Jolla
Sponsor: Neurotech Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06971939·Phase 4·Recruiting·Listed May 2025
Hydrus® Microstent New Enrollment Post-Approval Study
for Primary Open Angle Glaucoma
20 locations incl. Sacramento
Sponsor: Alcon Research
Sex: All·Age: 45+
Code: NCT04553523·Recruiting·Listed Sep 2020
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
for Stargardt Disease
10 locations incl. San Francisco
Sponsor: Ascidian Therapeutics, Inc
Sex: All·Age: 12+
Code: NCT06467344·Phase 1, Phase 2·Recruiting·Listed Jun 2024
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
for ARB
4 locations incl. Los Angeles
Sponsor: Opus Genetics, Inc
Sex: All·Age: 18+
Code: NCT07185256·Phase 1, Phase 2·Recruiting·Listed Sep 2025
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
for Stargardt Disease
8 locations incl. San Francisco
Sponsor: Ascidian Therapeutics, Inc
Sex: All·Age: 5+
Code: NCT06445322·Recruiting·Listed Jun 2024
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
for Presumed Ocular Histoplasmosis
2 locations incl. Cincinnati
Sponsor: Cincinnati Eye Institute, Southwest Ohio
Sex: All·Age: 18+
Code: NCT07695298·Phase 4·Recruiting·Listed Jul 10, 2026
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
for Corneal Transplant Failure
12 locations incl. Irvine
Sponsor: Massachusetts Eye and Ear Infirmary
Sex: All·Age: 18+
Code: NCT06753916·Phase 2·Recruiting·Listed Dec 2024
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
for Proliferative Vitreoretinopathy
1 location in Cincinnati
Sponsor: Cincinnati Eye Institute, Southwest Ohio
Sex: All·Age: 18+
Code: NCT06541574·Phase 2·Recruiting·Listed Aug 2024
More research sites in Cincinnati
- Cincinnati Children's Hospital Medical Center (281 trials)
- University of Cincinnati (102 trials)
- University of Cincinnati Medical Center (66 trials)
- Cincinnati Children's Hospital (45 trials)
- University of Cincinnati Cancer Center-UC Medical Center (43 trials)
- The Christ Hospital (36 trials)
- Good Samaritan Hospital - Cincinnati (35 trials)
- Bethesda North Hospital (34 trials)
- TriHealth Cancer Institute-Anderson (25 trials)
- TriHealth Cancer Institute-Westside (25 trials)
Explore more
Paid clinical trials in Cincinnati, OH · Ohio clinical trials